Eylea bests Lucentis in DME, but Avastin wins on cost
This article was originally published in Scrip
An investigator-sponsored clinical trial found that three vascular endothelial growth factor (VEGF) inhibitors work similarly well in about 75% of diabetic macular edema (DME), while Eylea (aflibercept) from Regeneron Pharmaceuticals outperformed Genentech's Lucentis (ranibizumab) and Avastin (bevacizumab) in the 25% of DME patients with more severe vision loss, but a separate physician opinion recommends off-label Avastin for most patients due to its much lower cost.
You may also be interested in...
Regeneron Pharmaceuticals Inc. executives emphasized the blockbuster potential of product candidates in the company's late-stage research and development pipeline on Aug. 4, while noting that the top-selling biologic Eylea (aflibercept) is facing increased reimbursement and competitive pressures.
The company, which has reported no R&D successes outside of its CGRP inhibitor platform, said verdiperstat did not differentiate from placebo on any endpoints in multiple system atrophy.
Private Company Edition: Jeito says its new first fund is Europe’s largest life science-focused fund. Illumina will use its venture capital to support tools, diagnostics, therapeutics and more. Also, IASO closed a $108m series C round and Amolyt raised $80m in series C financing.